Last reviewed · How we verify

administration of Cimzia®

University Hospital, Ghent · Phase 3 active Small molecule

administration of Cimzia® is a TNF inhibitor Small molecule drug developed by University Hospital, Ghent. It is currently in Phase 3 development for Moderate to severe Crohn's disease, Moderate to severe ulcerative colitis, Rheumatoid arthritis.

Cimzia is a fully human monoclonal antibody that selectively binds to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.

Cimzia is a fully human monoclonal antibody that selectively binds to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors. Used for Moderate to severe Crohn's disease, Moderate to severe ulcerative colitis, Rheumatoid arthritis.

At a glance

Generic nameadministration of Cimzia®
SponsorUniversity Hospital, Ghent
Drug classTNF inhibitor
TargetTNF
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

This action prevents the inflammatory effects of TNF, which is involved in the inflammatory process of various autoimmune diseases. By inhibiting TNF, Cimzia reduces inflammation and slows disease progression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about administration of Cimzia®

What is administration of Cimzia®?

administration of Cimzia® is a TNF inhibitor drug developed by University Hospital, Ghent, indicated for Moderate to severe Crohn's disease, Moderate to severe ulcerative colitis, Rheumatoid arthritis.

How does administration of Cimzia® work?

Cimzia is a fully human monoclonal antibody that selectively binds to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.

What is administration of Cimzia® used for?

administration of Cimzia® is indicated for Moderate to severe Crohn's disease, Moderate to severe ulcerative colitis, Rheumatoid arthritis, Psoriatic arthritis, Plaque psoriasis.

Who makes administration of Cimzia®?

administration of Cimzia® is developed by University Hospital, Ghent (see full University Hospital, Ghent pipeline at /company/university-hospital-ghent).

What drug class is administration of Cimzia® in?

administration of Cimzia® belongs to the TNF inhibitor class. See all TNF inhibitor drugs at /class/tnf-inhibitor.

What development phase is administration of Cimzia® in?

administration of Cimzia® is in Phase 3.

What are the side effects of administration of Cimzia®?

Common side effects of administration of Cimzia® include Upper respiratory tract infection, Nasopharyngitis, Headache, Fatigue, Injection site reaction.

What does administration of Cimzia® target?

administration of Cimzia® targets TNF and is a TNF inhibitor.

Related